{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:59:06Z","timestamp":1726473546472},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":782,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ejca.2011.02.012","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T22:54:44Z","timestamp":1306450484000},"page":"1328-1335","source":"Crossref","is-referenced-by-count":16,"title":["Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"2004-004473-29","registry":"10.18810\/euctr"}],"author":[{"given":"M.J.A.","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.E.M.","family":"Kitzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Brega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.02.012_b0005","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.13.9.1055","article-title":"Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular development","volume":"13","author":"Gale","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2011.02.012_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(00)79001-4","article-title":"New paradigms for the treatment of cancer; the role of anti-angiogenesis agents","volume":"79","author":"Cherrington","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ejca.2011.02.012_b0015","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.02.012_b0020","first-page":"3719","article-title":"The dermatofibrosarcoma protuberans-associated collagen type I alpha1\/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB","volume":"59","author":"Shimizu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.02.012_b0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1158\/1535-7163.MCT-05-0333","article-title":"SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity","volume":"5","author":"Patyna","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.02.012_b0030","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.02.012_b0035","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/1535-7163.MCT-03-0156","article-title":"Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248","volume":"5","author":"Potapova","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.02.012_b0040","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O\u2019farrell","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.02.012_b0045","doi-asserted-by":"crossref","unstructured":"Fiedler WM, Giaccone G, Lasch P, et al. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol. 2010 Jul 6. [Epub ahead of print].","DOI":"10.1093\/annonc\/mdq313"},{"key":"10.1016\/j.ejca.2011.02.012_b0050","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab\u2019, leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.02.012_b0055","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.02.012_b0060","doi-asserted-by":"crossref","first-page":"e8149","DOI":"10.1371\/journal.pone.0008149","article-title":"Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma","volume":"4","author":"K\u0142osowska-Wardega","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2011.02.012_b0065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.bjc.6603941","article-title":"Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts","volume":"97","author":"Vlahovic","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.02.012_b0070","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.02.012_b0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","article-title":"Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.02.012_b0080","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1200\/JCO.2005.05.0294","article-title":"Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer","volume":"24","author":"Harvey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.02.012_b0085","doi-asserted-by":"crossref","unstructured":"Robert F, Sandler A, Schiller JH, et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2009 Dec 31. [Epub ahead of print].","DOI":"10.1007\/s00280-009-1209-0"},{"key":"10.1016\/j.ejca.2011.02.012_b0090","doi-asserted-by":"crossref","unstructured":"Zurita AJ, Liu G, Hutson T, et al. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 2009;27:15s (suppl; abstract 5166).","DOI":"10.1200\/jco.2009.27.15_suppl.5166"},{"key":"10.1016\/j.ejca.2011.02.012_b0095","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0959-8049(94)90456-1","article-title":"Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group","volume":"30","author":"Aamdal","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.02.012_b0100","unstructured":"Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31a:S1\u20134."},{"key":"10.1016\/j.ejca.2011.02.012_b0105","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.02.012_b0110","doi-asserted-by":"crossref","unstructured":"Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast acnecr (ABC). J Clin Oncol 2010;28:18s (suppl, abstract LBA1010).","DOI":"10.1200\/jco.2010.28.18_suppl.lba1010"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911001110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911001110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T07:09:45Z","timestamp":1637737785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911001110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0959804911001110"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.02.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}